4,5,6-trimethyl-pyridin-2-ol | 76621-35-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4,5,6-trimethyl-pyridin-2-ol
• 英文别名: 4,5,6-trimethyl-1H-pyridin-2-one
• CAS: 76621-35-7
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: CMSSDZQNILGIDR-UHFFFAOYSA-N

物化性质

• 熔点：
  252 °C
• 沸点：
  299.3±13.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,5,6-trimethyl-pyridin-2-ol 在 potassium permanganate 、 五氯化磷 、 氢碘酸 、 锌 作用下， 生成 pyridine-2,3,4-tricarboxylic acid
  参考文献：
  名称：

  Dual Effect of Nucleotides on P2Y Receptors

  摘要：

  The interaction of ADP, 2MeSADP, and ADP betaS with the adenine nucleotide receptor P2Y(1) in the hP2Y(1)-1321N1 cell line and of UDP with a receptor or receptors recognizing pyrimidine nucleotides in NG108-15 cells was studied over a wide range of ligand concentrations, Bell-shaped dose-response curves for stimulation of phosphoinositide hydrolysis were obtained in these cells, This dual behavior of the agonists studied was characterized by two dissociation constants, K-agon and K-antag, which quantify the agonistic and antagonistic activity of these ligands and can be compared with the conventional EC50 and IC50 values, respectively. The data revealed a common pattern of agonistic and antagonistic behavior of nucleoside diphosphates and their derivatives at these two types of P2Y receptors, pointing to some similar properties of their nucleotide binding sites.

  DOI：

  10.1080/15216540050212105
• 作为产物：
  描述：

  3-甲基-2,4-戊烷二酮 在 硫酸 、 水 作用下， 生成 4,5,6-trimethyl-pyridin-2-ol
  参考文献：
  名称：

  Synthese von 2-Oxy-imidazolo-(5′,4′:2,3)-pyridinen Synthesen stickstoffhaltiger Heterocyclen, XII. Mitteilung

  摘要：

  DOI：

  10.1002/ardp.19572900104

文献信息

• [EN] PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR<br/>[FR] DERIVES DE PYRIDINE ET LEUR UTILISATION EN TANT QUE MEDICAMENTS POUR LE TRAITEMENT DES MALADIES LIEES AUX RECEPTEURS MCH
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2006035967A1

  公开（公告）日：2006-04-06

  The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了化学式（I）的新型取代吡啶化合物，其作为MCH受体拮抗剂。这些组合物及其药物组合物在预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴饮暴食障碍包括暴食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾症方面具有用处。
• Heterocylic antiviral compounds
  申请人：Lemoine Remy

  公开号：US20070191335A1

  公开（公告）日：2007-08-16

  Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R 1 -R 3 R 6c and X 1 are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV-1) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treating diseases mediated by the CCR5 receptor.

  足迹化学受体拮抗剂，特别是根据式(I)的3,7-二氮杂双环[3.3.0]辛烷化合物，其中R1-R3R6c和X1如本文所定义，是足迹化学CCR5受体的拮抗剂，可用于治疗或预防人类免疫缺陷病毒（HIV-1）感染，或治疗艾滋病或ARC。该发明还提供了用于治疗通过CCR5拮抗剂缓解的疾病的方法。该发明包括药物组合物和使用这些化合物治疗通过CCR5受体介导的疾病的方法。
• Reactions of 1-unsubstituted tautomeric 2-pyridones with benzyne.
  作者：MASAYUKI KUZUYA、AKIHIRO NOGUCHI、SHOJI KAMIYA、TAKACHIYO OKUDA

  DOI：10.1248/cpb.33.2313

  日期：——

  The reactions of 1-unsubstituted 2-pyridones with benzyne afforded the Diels-Alder adduct, 5, 6-benzo-2-azabarrelen-3 (2H)-ones, together with a large amount of the Michael-type adduct, 2-phenoxypyridines.

  1-未取代的2-吡啶酮与苯炔的反应生成了Diels-Alder加成产物5, 6-苯并-2-氮杂巴雷ланы-3 (2H)-酮，同时生成了大量的迈克尔型加成产物2-苯氧基吡啶。
• The Structure–Reactivity–Chemoselectivity Relationship on the Reactions of 1-Unsubstituted Tautomeric 2-Pyridones with Benzyne
  作者：Masayuki Kuzuya、Akihiro Noguchi、Ei-ichi Mano、Takachiyo Okuda

  DOI：10.1246/bcsj.58.1149

  日期：1985.4

  The reactions of 2-pyridones with benzyne were investigated in order to gain some insight into the structure–reactivity–chemoselectivity relationship involved in the tautomeric systems. All reactions examined have resulted in the formation of Diels-Alder and Michael-type adducts. It has been shown that the Diels-Alder reactivities were well correlated with the HOMO energy levels of the 2-pyridone form and the yields of the Michael-type adduct were closely associated with the tautomeric equilibria. In summary, the chemoselectivities of 2-pyridones in the reaction with benzyne were largely affected by the tautomeric properties.

  对2-吡啶酮与苯炔的反应进行了研究，以获取有关该互变异构体系中结构-反应性-化学选择性关系的深入见解。所有检查的反应都导致了狄尔斯-阿尔德和迈克尔型加成物的形成。研究表明，狄尔斯-阿尔德的反应性与2-吡啶酮形式的最高占据分子轨道（HOMO）能级之间有良好的相关性，而迈克尔型加成物的产率与互变平衡密切相关。总之，2-吡啶酮与苯炔反应中的化学选择性受到互变特性的很大影响。
• PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS
  申请人：Baroudy Bahige M.

  公开号：US20080188485A1

  公开（公告）日：2008-08-07

  The use of CCR 5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R 3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R 4 , R 5 and R 7 are hydrogen or alkyl; R 6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  本发明涉及CCR5拮抗剂的使用，其化学式为或其药学上可接受的盐，其中R是可选的取代苯基、吡啶基、噻吩基或萘基；R1是氢或烷基；R2是取代苯基、取代杂环芳基、萘基、芴基、二苯甲基或可选取代的苯基或杂环芳基烷基；R3是氢、烷基、烷氧基烷基、环烷基、环烷基烷基或可选取代的苯基、苯基烷基、萘基、萘基烷基、杂环芳基或杂环芳基烷基；R4、R5和R7是氢或烷基；R6是氢、烷基或烯基；用于治疗HIV、固体器官移植排斥、移植物抗宿主病、关节炎、类风湿性关节炎、炎症性肠病、特应性皮炎、牛皮癣、哮喘、过敏或多发性硬化症，以及新型化合物、包含它们的药物组合物，以及本发明的CCR5拮抗剂与用于治疗HIV或治疗炎症性疾病的抗病毒药物的组合。